Since launching its sponsorship policy in 2021, IHU ICAN has been raising awareness of cardiometabolic diseases (CMDs) in the philanthropic landscape. Public ignorance of these conditions and the serious cardiovascular complications associated with them has meant that this public health issue has flown under the radar of charitable giving for many years.
However, sponsorship is an accelerator of innovation and enables our researchers to go further in their research work.
Join us in our cause!
How can we support research into cardiometabolism?
Supporting IHU ICAN means accelerating scientific and medical discoveries in a rapidly changing field. Our multidisciplinary teams bring together clinicians, researchers, engineers, data scientists, and industry players to understand the complex interactions between the heart, metabolism, liver, and microbiota.
Several options are available to you depending on your profile and means:
Make a donation
You can make a donation online on the secure IHU ICAN website. Your contribution directly funds research projects, the purchase of scientific equipment, and support for young researchers.
For a company, your sponsorship entitles you to tax benefits thanks to a tax reduction of 60% of the donation amount on your corporate income tax (CIT), and highlights your social commitment.
For individuals, your donation entitles you to tax benefits, thanks to a tax reduction of 66% of the amount of your donation on your income tax (IR), and 75% on your real estate wealth tax (IFI).
Become a patron
Corporate sponsors play a key role in the development of our research programs.
As a patron of the ICAN Institute, you can:
- Support a specific scientific project,
- Participate in the acquisition of innovative equipment for our technology platforms,
- Fund a research chair,
- Contribute to a therapeutic education or prevention program,
- Participate in solidarity events (online challenges, conferences, national campaigns, etc.).
Salary rounding
Corporate sponsors play a key role in the development of our research programs. As a sponsor of L’arrondi sur salaire is a donation system that allows companies and their employees to financially support an association or foundation through micro-donations rounded down to the nearest euro from their salary (or another amount of their choice). For example, on a salary of €2,100.53, 53 cents are donated to an association every month.
- The employer may choose to match donations (for example, by doubling the amount donated by the employee).
- Employees are free to choose whether or not to participate in the scheme, the amount they wish to contribute, and the duration of their participation.
- Donations are eligible for a tax reduction of between 66% and 75% of the amount donated.
Rounding in cash registers or online
By implementing rounding up at the checkout or online, a company can offer each customer the option of rounding up the amount of their purchase in-store or online to the nearest euro, thereby making a micro-donation to support research conducted at the IHU ICAN.
These contributions, when combined, become a powerful lever for solidarity and demonstrate your concrete commitment to society. By joining the solidarity rounding program for the benefit of IHU ICAN, you are helping to advance the prevention, diagnosis, and treatment of cardiometabolic diseases.
Focus on sponsorship of the OPTIM-HCM project to accelerate research in cardiogenetics
Hypertrophic cardiomyopathy (HCM) is a genetic disease that affects approximately 1 in 500 people in the general population. It is a major cause of sudden cardiac death, particularly in young people and athletes under the age of 35. Currently, the only effective prevention for HCM is the implantation of an implantable cardioverter defibrillator (ICD).
Identifying patients who require this device is essential to prevent a tragic progression of the disease.
This is the objective of the OPTIM project led by Professor Philippe Charron and funded in part by the Le Triomphe du Coeur and Sicame Group endowment funds. This study aims to improve the prediction of sudden cardiac death in patients with hypertrophic cardiomyopathy. The total budget for this extensive study is over €1 million, and it could not be carried out in its entirety without the commitment of sponsors.
A word from our sponsors
“The Le Triomphe du Coeur Endowment Fund was created in 2021 in tribute to my husband, who died too young from sudden adult death due to hypertrophic cardiomyopathy, a hereditary heart disease that is often silent but fatal without early diagnosis. His passing reinforced my conviction that medical research is essential to prevent such tragedies and save lives. That is why we support the OPTIM project. Thanks to donations and sponsorship, Le Triomphe du Coeur is actively committed to advancing research. We are convinced that every scientific advance helps to protect future generations and prevent other families from experiencing the same pain.”
Virginie NAHRA, President of the Triomphe du Cœur Endowment Fund
Medical research quickly became a priority for the Sicame Endowment Fund. We felt compelled to contribute, even if our contribution is modest compared to the scale of the research programs. For us, this is an opportunity to provide experts and researchers with the technological and scientific resources they need to make advances in healthcare that will benefit everyone. Meeting the women and men at IHU-ICAN was inspiring and reinforced our commitment to philanthropy. It’s about being the invisible ones who support medical research over the long term.”
Nadine VALET, Vice President of the Sicame Group Endowment Fund
A word from the project’s principal investigator
“Sponsorship is very important in supporting innovations that benefit patients. As coordinator of the Reference Center for Hereditary or Rare Heart Diseases and head of the OPTIM-HCM research project, I am delighted with the collaboration that has been established with sponsors Le Triomphe du Coeur and the Sicame Group endowment fund since the end of 2023. Their sponsorship has actively supported our research project on the prevention of sudden death in hypertrophic cardiomyopathy, greatly facilitating its progress, particularly in terms of data review by the MRI core lab. In addition to their financial support, they also carry out communication activities that play a very important role in raising public awareness of cardiometabolic diseases.”
Professor Philippe CHARRON
PU-PH (leader of the OPTIM-HCM project) Head of the Genomics and Physiopathology of Myocardial Diseases Research Team UMR 1166/IHU ICAN and Coordinator of the Reference Center for Hereditary or Rare Heart Diseases
Supporting research into cardiometabolic diseases means investing in life
Every donation helps accelerate discoveries, strengthen prevention, and improve patient care. By joining the community of sponsors and donors of the IHU ICAN, you are actively participating in the fight against cardiometabolic diseases, a major public health challenge of the 21st century.
Together, let’s be active participants in healthcare!
